About Canary

A Message from the CEO

Canary Oncoceutics was founded by academics and experts from world-leading institutions. Canary Oncoceutics is driven by three fundamental pillars: quality, patient care, and patient safety. Keeping this in mind, the Company has spent a great deal of time and effort in creating what is likely the most complete and useful comprehensive genomic panel available worldwide.

Our genomic panel has been validated for absolute sensitivity and specificity. Our CLIA-certified and CAP-accredited laboratories conduct tests under stringent conditions giving physicians and their patients confidence in the quality of our results.In addition to these driving principles, the Canary team provides personal support to the patient and physician both in interpreting the reports and providing guidance to the families of the patient. And with a 14-day turnaround time, there is only a short wait until the results are transmitted to the physician. Many patients and their families have benefited from our tests because of their accuracy and sensitivity.

A recent case highlights this: A 57-year-old male was diagnosed with lung cancer and a small gene panel was prescribed by his physician. When those results came back without detecting any mutations or alterations, the physician recommended the Canary AcuityTM comprehensive genomic panel. We detected a rare mutation fusion alteration in the RET gene called a fusion. The physician and patient were delighted about this because there are approved drugs for this mutation fusion and he could be started on that therapy immediately.

We are proud of the quality of our tests and are delighted that the oncology community recognizes its power and utility.

Thank you for trusting us with the molecular diagnosis you and your family deserve.

Harry M. Lander, Ph.D.

Global CEO

what we do

With our revolutionary Canary Predict ^TM Engine, we are developing tests that can predict therapeutic outcomes for colon, lung, breast, head and neck and other cancers for a specific patient. Other parameters useful for the physician include progression free survival, overall survival and tumor microenvironment information such as tumor infiltrating lymphocytes and tumor lymphoid structures.

We expect to have our first RNA tests available soon.

Canary's comprehensive DNA test, Canary Acuity^TM, is by far the most complete DNA tumor-profiling test available on the market today. Our advantages include:

Extensive Gene Testing: Examining hundreds more cancer-causing genes with clinically relevant treatment options, we provide the most complete diagnostic test available.
Enhanced Predictive Capabilities: In addition to TMB (Tumor Mutational Burden), MSI (Microsatellite Instability), and HRD (Homologous Recombination Deficiency), our comprehensive test goes a step further. It also accurately predicts TCR clonality, equipping treating oncologists with valuable information on personalized immunotherapy strategies and the ability to assess the therapeutic response over time.
Detailed Metabolic Pathways: Providing clinicians with detailed metabolic pathways associated with each mutation allows for a clear understanding of the underlying pathology.
Comprehensive Germline Variant Testing: By testing 637 germline variants, our test sheds light on the personalized pharmacogenomics of each patient. This information gives clinicians invaluable insight into patient-specific toxicities that may influence treatment selection.
Complete ACMG Oncology Germline Mutational Analysis: Testing all oncology-related genes recommended by the American College of Medical Genetics and Genomics provides screening for germline mutations which are reportable incidental findings.

If you are a practicing oncologist and want to compare our test, please contact us - we can provide you with free tests so you can do a side-by-side comparison.

A Message from the CEO

what we do

Get In Touch

Address

Phone

Email

Phone